Magdalena Cedzynska
National Research Institute of Oncology, PolandPresentation Title:
The importance of quitting for the results of anti-cancer treatment in non-tobacco-related cancers – literature review
Abstract
Introduction: Tobacco use is linked to 15 distinct types of cancer and accounts for nearly 30% of all cancer-related deaths. Research suggests that smoking following a cancer diagnosis not only hampers treatment effectiveness and tolerance but also that quitting smoking post-diagnosis yields substantial advantages.
Methods: Literature review from PubMed database.
Results: For patients with cancers not related to smoking, such as breast, skin, or brain cancer, smoking still poses significant risks. It has been proven that smoking cessation brings various benefits. In the case of breast cancer, smoking can diminish the effectiveness of chemotherapy and other cancer treatments. Research suggests that smoking can interfere with the metabolism of chemotherapy drugs, potentially leading to lower drug levels in the bloodstream and reduced effectiveness. Smoking during breast cancer treatment can exacerbate treatment-related side effects. Breast cancer patients who smoke may experience slower recovery times after surgery, which can delay subsequent treatments. Hormone receptor-positive breast cancers are commonly treated with hormone therapy. Smoking has been shown to reduce the effectiveness of hormone therapy and increase the risk of recurrence in this subtype of breast cancer. Brain cancers- the impact of smoking on treatment outcomes can vary depending on factors such as the type and stage of cancer, the specific treatment regimen, and individual patient characteristics. A prospective study found a significant association between smoking and reduced survival among glioblastoma patients, suggesting that smoking may negatively impact treatment outcomes in this population. Some retrospective studies found that smoking was associated with poorer treatment response and worse prognosis in patients with brain metastases.In the case of melanoma, smoking at least 20 cigarettes a day was associated with a 2-fold higher risk of death from melanoma.
Conclusion: Efforts to reduce smoking prevalence are essential not only for cancer prevention but also for improving overall health outcomes and reducing healthcare costs associated with smoking-related illnesses. In many national and international projects, clinical trials and observations. She has been coordinated and lectured of over 50 courses on tobacco dependence treatment for health professionals all over the Poland. She is co‐author over 30 scientific publications (peer‐reviewed), 7 books, chapters, monographs and educational programs. She gave many oral presentations at conferences, abstracts and posters.
Biography
Dr
Magdalena Cedzynska, psychologist, senior researcher, director of Smoking
Cessation Service at National Research Institute of Oncology. She is engaged in
cancer primary prevention through tobacco control with special attention to
treatment of tobacco dependence. For more than 12 years she took part as a
researcher and coordinator in many national and international projects,
clinical trials and observations. She has been coordinated and lectured of over
50 courses on tobacco dependence treatment for health professionals all over
the Poland. She is co‐author over 30 scientific publications (peer‐reviewed), 7
books, chapters, monographs and educational programs. She gave many oral
presentations at conferences, abstracts and posters.
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801 USA
Mail us at
Program Enquiry
oncology@scientexconferences.com
General Enquiry
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
oncology@scientexconferences.com
Our Social Presence
Call us at
USA :(+1) 323 677 0554